GlassScriptPhysician profile
Justin Ross Porter
NPI 1104098961
$7,676.44
in general payments reported to CMS, 2019-2025
34 companies · $636 in 2025
The $636 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $1,911 · 2021: $984 · 2022: $838 · 2023: $490 · 2024: $566 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,508.05 | 2019-2025 | Proclaim |
| Nevro Corp. | $2,076.68 | 2019-2024 | Senza |
| Globus Medical, INC. | $407.71 | 2025 | Senza, Omnia |
| Medtronic, INC. | $404.01 | 2021-2025 | Intellis Adaptivestim, Synchromedii |
| Medtronic USA, INC. | $284.52 | 2019-2020 | |
| Abbvie INC. | $250.96 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $248.12 | 2019-2022 | |
| Horizon Therapeutics Plc | $214.23 | 2019-2022 | |
| Boston Scientific Corporation | $174.92 | 2020-2024 | |
| Stryker Corporation | $152.86 | 2019 | |
| Amgen INC. | $107.99 | 2020-2022 | |
| Allergan, INC. | $74.46 | 2019-2022 | |
| Vertos Medical, INC. | $68.68 | 2020 | |
| Spr Therapeutics, INC | $67.61 | 2022-2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.75 | 2021-2023 | Relistor |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $60.27 | 2020-2021 | |
| Vertiflex, INC. | $53.50 | 2019 | |
| Saluda Medical Americas, INC. | $53.24 | 2023-2025 | Evoke, Evoke Scs |
| Pacira Therapeutics, INC. | $47.04 | 2019-2020 | |
| Avanos Medical | $45.08 | 2021 | |
| Pfizer INC. | $34.15 | 2019 | |
| Almatica Pharma LLC | $30.22 | 2023 | Gralise |
| Collegium Pharmaceutical, INC. | $29.79 | 2023-2024 | Belbuca |
| Kowa Pharmaceuticals America, INC. | $27.92 | 2022 | |
| Si-Bone, INC. | $27.20 | 2019 | |
| Zyla Life Sciences, INC. | $25.82 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $23.18 | 2023 | |
| Forte Bio-Pharma LLC | $20.26 | 2024 | Prolate, Nalocet |
| Ibsa Pharma INC. | $19.30 | 2024 | Licart, Tirosint |
| Averitas Pharma INC. | $18.36 | 2024 | Qutenza |
| Bioventus LLC | $16.29 | 2021 | |
| Merck Sharp & Dohme LLC | $14.95 | 2022 | |
| Nalu Medical, INC. | $13.60 | 2021 | |
| Assertio Therapeutics, INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.